Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
156.39
Dollar change
+1.31
Percentage change
0.84
%
Index- P/E- EPS (ttm)-8.50 Insider Own0.91% Shs Outstand95.36M Perf Week-4.47%
Market Cap14.95B Forward P/E- EPS next Y-2.81 Insider Trans-5.48% Shs Float94.71M Perf Month-12.38%
Income-881.71M PEG- EPS next Q-2.56 Inst Own46.50% Short Float1.83% Perf Quarter-12.60%
Sales2.46B P/S6.08 EPS this Y1.12% Inst Trans-0.41% Short Ratio5.93 Perf Half Y-18.62%
Book/sh33.82 P/B4.62 EPS next Y66.40% ROA-14.47% Short Interest1.73M Perf Year-28.90%
Cash/sh33.33 P/C4.69 EPS next 5Y- ROE-22.26% 52W Range132.95 - 272.49 Perf YTD-13.29%
Dividend Est.- P/FCF- EPS past 5Y5.63% ROI-23.47% 52W High-42.61% Beta0.61
Dividend TTM- Quick Ratio2.09 Sales past 5Y92.60% Gross Margin81.13% 52W Low17.63% ATR (14)6.54
Dividend Ex-Date- Current Ratio2.32 EPS Y/Y TTM56.56% Oper. Margin-49.12% RSI (14)45.35 Volatility2.57% 3.66%
Employees10000 Debt/Eq0.26 Sales Y/Y TTM73.65% Profit Margin-35.86% Recom1.19 Target Price269.83
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q17.71% Payout- Rel Volume0.36 Prev Close155.08
Sales Surprise-0.41% EPS Surprise-0.20% Sales Q/Q66.91% EarningsFeb 26 BMO Avg Volume291.81K Price156.39
SMA20-4.28% SMA50-1.20% SMA200-13.60% Trades Volume104,129 Change0.84%
Date Action Analyst Rating Change Price Target Change
Feb-06-24Resumed JP Morgan Overweight $185
Sep-12-23Initiated Macquarie Outperform $259
Aug-17-23Initiated Jefferies Buy $287
Jul-17-23Initiated Citigroup Buy $275
Jun-30-23Downgrade Bernstein Outperform → Mkt Perform $335 → $196
Jan-12-23Initiated Daiwa Securities Buy $308
Oct-13-22Upgrade SVB Leerink Mkt Perform → Outperform $177 → $200
Oct-13-22Upgrade Guggenheim Neutral → Buy $205
Aug-09-22Resumed JP Morgan Overweight $296
Mar-17-22Downgrade SVB Leerink Outperform → Mkt Perform $300 → $177
Mar-17-24 08:50AM
Mar-14-24 04:28PM
02:54PM
02:14PM
Mar-13-24 08:00AM
05:19PM Loading…
Mar-07-24 05:19PM
03:39PM
03:35PM
01:10PM
Mar-06-24 06:00AM
Feb-29-24 10:00AM
Feb-28-24 08:05AM
Feb-27-24 06:00AM
12:05AM
Feb-26-24 06:32AM
06:00AM Loading…
06:00AM
05:00AM
Feb-20-24 10:49AM
Feb-13-24 12:58PM
Feb-07-24 06:47AM
Feb-02-24 05:04AM
Jan-31-24 06:47AM
Jan-23-24 06:00AM
Jan-04-24 09:26PM
Dec-27-23 08:06PM
Dec-22-23 06:00AM
Dec-21-23 06:01AM
Dec-19-23 11:41AM
Nov-30-23 09:55AM
Nov-29-23 04:01PM
06:00AM Loading…
Nov-28-23 06:00AM
Nov-22-23 06:04AM
Nov-21-23 07:14AM
06:59AM
06:14AM
06:00AM
Nov-17-23 06:00AM
Nov-15-23 05:05AM
Nov-14-23 05:07PM
09:55AM
Nov-10-23 07:00AM
12:22AM
Nov-09-23 04:01PM
Nov-08-23 06:00AM
Oct-20-23 06:00AM
Oct-17-23 04:01PM
04:01PM
Oct-16-23 06:00AM
Oct-13-23 11:51AM
Oct-05-23 05:17PM
Sep-19-23 06:22AM
06:15AM
06:10AM
06:00AM
Sep-12-23 09:53AM
Aug-31-23 07:00AM
Aug-17-23 09:39AM
Aug-02-23 06:00AM
Jul-21-23 07:50AM
Jul-14-23 09:58AM
Jul-13-23 08:12AM
Jul-12-23 07:00AM
Jul-10-23 07:00AM
Jul-07-23 07:00AM
Jun-15-23 01:20PM
08:37AM
03:00AM
Jun-09-23 03:01AM
May-30-23 07:00AM
07:00AM
May-25-23 05:05PM
02:45PM
May-24-23 07:00AM
May-17-23 07:00AM
May-11-23 07:02AM
May-09-23 09:29AM
May-06-23 08:00AM
May-05-23 06:01AM
May-04-23 07:00AM
Apr-28-23 01:39PM
Apr-26-23 10:27AM
Apr-25-23 08:45AM
07:00AM
Apr-20-23 01:50PM
07:00AM
Apr-19-23 07:22PM
Apr-17-23 02:32PM
02:32PM
02:30PM
02:30PM
08:41AM
Apr-14-23 02:45PM
Apr-13-23 12:02PM
10:45AM
07:00AM
Apr-10-23 03:07AM
Apr-06-23 05:24PM
Mar-30-23 07:00AM
Mar-27-23 06:25AM
Mar-25-23 02:53PM
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OYLER JOHNChief Executive OfficerMar 13 '24Sale177.5612,3322,189,6480Mar 14 05:23 PM
OYLER JOHNChief Executive OfficerMar 12 '24Sale164.0237,6686,178,36912,332Mar 14 05:23 PM
Wang Julia AijunChief Financial OfficerFeb 29 '24Sale167.0839766,3310Mar 04 05:22 PM
Lee Chan HenrySVP, General CounselJul 31 '23Sale216.26791171,0590Aug 02 05:10 PM
Wang Julia AijunChief Financial OfficerJul 03 '23Sale179.5547284,7470Jul 06 05:02 PM
Wu XiaobinPresident, COO & GM ChinaJun 26 '23Sale182.371,495272,6360Jun 27 05:20 PM
Wang LaiGlobal Head of R&DJun 26 '23Sale181.921,108201,5670Jun 27 05:24 PM
Wang Julia AijunChief Financial OfficerJun 23 '23Sale182.85840153,5940Jun 27 05:22 PM
Sanders Corazon (Corsee) D.DirectorJun 23 '23Sale182.32578105,3810Jun 27 05:21 PM
Wang LaiGlobal Head of R&DJun 20 '23Sale192.421,325254,9550Jun 20 06:53 PM
HHLR ADVISORS, LTD.10% OwnerJun 14 '23Sale207.72273,72856,857,986142,888,241Jun 15 07:25 PM
HHLR ADVISORS, LTD.10% OwnerJun 13 '23Sale183.31924,400169,448,353143,161,969Jun 15 07:25 PM
HHLR ADVISORS, LTD.10% OwnerJun 12 '23Sale195.211,250,212244,057,178144,086,369Jun 12 09:57 PM
HHLR ADVISORS, LTD.10% OwnerJun 09 '23Sale182.89542,65299,244,890145,336,581Jun 12 09:57 PM
HHLR ADVISORS, LTD.10% OwnerJun 08 '23Sale218.141,163,825253,881,790145,879,233Jun 12 09:57 PM
Wu XiaobinPresident, COO & GM ChinaJun 07 '23Sale224.733,291739,5990Jun 09 05:44 PM
Wang LaiGlobal Head of R&DJun 07 '23Sale224.74462103,8280Jun 09 05:46 PM
Wu XiaobinPresident, COO & GM ChinaMay 08 '23Sale253.727,0001,776,0370May 10 04:44 PM